Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells $776,100.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $19.90, for a total value of $776,100.00. Following the completion of the sale, the chief executive officer owned 802,317 shares of the company’s stock, valued at $15,966,108.30. The trade was a 4.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Xingjuan Chao also recently made the following trade(s):

• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.
• On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The shares were sold at an average price of $18.00, for a total value of $108,540.00.
• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $20.10, for a total value of $783,900.00.

CeriBell Trading Down 0.4%

CBLL stock traded down $0.08 during trading on Friday, hitting $19.56. The company had a trading volume of 197,196 shares, compared to its average volume of 364,622. The business has a 50-day moving average of $18.67 and a 200-day moving average of $19.65. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The stock has a market cap of $742.17 million, a PE ratio of -12.00 and a beta of 0.77. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The firm had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. Research analysts predict that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on CBLL shares. Canaccord Genuity Group dropped their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

Institutional Investors Weigh In On CeriBell

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its position in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after purchasing an additional 374,179 shares in the last quarter. Rhumbline Advisers increased its position in CeriBell by 109.9% in the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after buying an additional 17,177 shares in the last quarter. New York State Common Retirement Fund raised its stake in CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the period. Quantbot Technologies LP raised its stake in CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after buying an additional 6,401 shares during the period. Finally, Invesco Ltd. acquired a new stake in CeriBell in the second quarter valued at approximately $197,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.